Amgen Inc. is hoping to take a patent dispute with Sanofi-Aventis U.S. LLC and Regeneron Pharmaceuticals Inc. to the Supreme Court in a patent fight over competing high cholesterol drugs.
How the court decides could have substantial implications for companies that develop antibody-based drugs, including in the burgeoning field of cancer immunotherapy, under which the law generally has enabled companies to make relatively broad patent claims based on a limited number of described antibody types.
Amgen’s Repatha (evolocumab) competes with Praluent (alirocumab), offered jointly by Sanofi and Regeneron. Each drug is used to lower “bad” LDL ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.